Format

Send to

Choose Destination
Euro Surveill. 2013 Jan 31;18(5). pii: 20394.

Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada's sentinel surveillance network, January 2013.

Author information

1
British Columbia Centre for Disease Control, Vancouver, Canada. danuta.skowronski@bccdc.ca

Abstract

The 2012/13 influenza season in Canada has been characterised to date by early and moderately severe activity, dominated (90%) by the A(H3N2) subtype. Vaccine effectiveness (VE) was assessed in January 2013 by Canada's sentinel surveillance network using a test-negative case-control design. Interim adjusted-VE against medically attended laboratory-confirmed influenza A(H3N2) infection was 45% (95% CI: 13-66). Influenza A(H3N2) viruses in Canada are similar to the vaccine, based on haemagglutination inhibition; however, antigenic site mutations are described in the haemagglutinin gene.

PMID:
23399422
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for European Centre for Disease Prevention and Control (ECDC)
Loading ...
Support Center